Why Is It Moving? Analyzing The Upward Movement in Moderna's Stock Today

April 13, 2021 10:40 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Moderna's Stock Price And Volume Action

Moderna's (NASDAQ:MRNA) stock is trading up 7.78% to a price of $149.8. Tuesday the stock has been traded at a volume of 6.37 million, about 78.48% of its recent 30-day volume average of 8.11 million.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Moderna shares are trading higher after the U.S. calls for a pause on competitor J&J's COVID-19 vaccine after blood clotting cases.

Insights On Recent Price Action

The stock's 50-day moving average was $149.25 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $189.26 and fallen to a low of $31.32.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.


Movers Trading Ideas

Related Articles

Why Moderna Is Trading Higher Today

Moderna's Stock Price And Volume Action Moderna (NASDAQ:MRNA) is currently up 11.33% to a price of $142.71. The stock's volume is currently 4.16 million, which is roughly 18.94% of its recent 30-day volume average of 21.97 million. read more

Why Is It Moving? Looking At Moderna's Price Action Today

The Price And Volume Action In Moderna's Stock Today Moderna (NASDAQ:MRNA) is currently up 4.79% to a price of $131.0. Thursday the stock has been traded at a volume of 3.41 million, about 14.63% of its recent 30-day volume average of 23.28 million. read more

What's Going On With Moderna Stock Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 3.18% at $165.60 in Friday's pre-market session, recovering some of the losses following the company's first-quarter earnings report. read more

Stocks Of Vaccine Manufacturers Move Lower Following Report Pres Biden Said He Plans To Back WTO Waiver For Vaccine Intellectual Property, Will Discuss Later Wednesday

-Reuters-Reuters read more